CAMBRIDGE, UK — 7 May 2026 — Retinitis pigmentosa (RP), the most common inherited retinal dystrophy, affects roughly 1 in 4,000 people, or approximately 2 million people globally and around 84,000 in the United States. Today, fewer than 1% of those patients have access to a disease-modifying treatment option. By 2033, that picture could change substantially: Gene Scope Intelligence projects that approximately 9,100 RP patients will be treated with gene therapies in 2033 alone across 10 high-income markets, with approximately 27,600 treated cumulatively through 2033, supporting annual revenues of approximately $3.434 billion in 2033 under base-case pricing.
A new MarketVIEW commercial opportunity assessment from Gene Scope Intelligence, covering RP through 2040, quantifies that opportunity asset by asset, genotype by genotype, and market by market.
A 99% unmet need and an inflection point from 2026 onward:
RP is genetically heterogeneous, with more than 200 disease-causing genes identified to date. Autosomal recessive forms predominate, alongside substantial autosomal dominant and X-linked subsets. Current management is supportive, focused on low-vision aids, complication management and genetic counselling. Luxturna (voretigene neparvovec) remains the only approved gene therapy for RP and addresses an estimated 650 eligible patients with biallelic RPE65 mutations in the U.S., leaving the remaining ~99% of RP patients without a disease-modifying option.
That status quo is now under sustained pressure from the most active gene therapy pipeline in ophthalmology outside dry AMD, with five pivotal or near-pivotal readouts and at least two BLAs converging within an 18-month window:
Nanoscope’s MCO-010 — a gene-agnostic optogenetic therapy. A rolling BLA was initiated in June 2025, the first for a gene-agnostic retinal gene therapy, following RESTORE Phase 2b/3 results showing approximately three lines of visual-acuity gain sustained through three years.
Ocugen’s OCU400 — a gene-agnostic modifier therapy. Phase 3 liMeliGhT enrolment (n=140) was completed in March 2026; topline data are expected in Q1 2027; a rolling BLA is planned.
Beacon Therapeutics’ Laru-zova — for X-linked RP. Pivotal Phase 2/3 VISTA enrolment was completed in July 2025; topline data are expected in H2 2026.
Janssen/J&J’s Bota-vec — for X-linked RP. Phase 3 LUMEOS missed its primary endpoint in May 2025, creating competitive space for Beacon, 4DMT and others targeting the same genotype.
A second wave is building behind these programmes: SparingVision’s SPVN06 (PRODYGY neuroprotection; n=33 dosed) and SPVN20 (NYRVANA optogenetic; first patient dosed in October 2025); Ray Therapeutics’ RTx-015 (FDA RMAT designation in April 2026); 4DMT’s 4D-125 in XLRP via intravitreal delivery; GenSight’s optogenetic GS030 (PIONEER); PYC Therapeutics’ VP-001 in PRPF31-associated RP, advancing toward Phase 3; and Sepul Bio’s ultevursen (Phase 2b LUNA; n=81) for USH2A-associated RP.
Author commentary:
“Retinitis pigmentosa has been a graveyard of late-stage gene therapy programmes, but the next 18 months will reset that narrative. With a rolling BLA already underway for the first gene-agnostic retinal gene therapy and four more pivotal datasets due before the end of 2027, the strategic question is no longer whether gene therapy works in RP; it is which modality and which genotype capture share first, and at what price,” said Hari Savopoulos, Gene Scope Intelligence.
What the report delivers:
This is a new patient-based commercial opportunity assessment forecasting gene therapy uptake and revenues in RP through 2040 across 10 high-income developed markets. Deliverables include an interactive Excel forecast model and an approximately 125-slide executive presentation.
Differentiating features:
Disease-stage segmentation across the patient pool, with separate forecasts for early- to mid-stage and late-stage RP. This reflects the clinically meaningful split for differentiating asset positioning, such as MCO-010 in late-stage disease versus OCU400 in early- to mid-stage disease, with revenue and patient counts tracked independently.
Four age-stratified cohorts (<18, 19–44, 45–64 and ≥65), built bottom-up from single-year-of-age country populations. This is rare in syndicated forecasts and material to paediatric versus adult pricing and access scenarios.
Three pricing scenarios per country: a low scenario, a Luxturna-anchored scenario and a high scenario, applied across all 10 markets and aggregated to global, North American, EU5 and developed-rest-of-world views.
Fully transparent and editable assumptions across epidemiology, diagnosis rate, disease-stage split, country-specific uptake curves (launch, medium-term and long-term phases) and pricing, allowing buyers to stress-test the base case in minutes.
A 10-market geographic build-up covering the U.S., Canada, France, Germany, Spain, Italy, the UK, Australia, Japan and South Korea. North America accounts for approximately 50% of 2033 treated-patient volume and approximately 64% of 2033 revenue, with regional pricing reconciled to the $3.4 billion projection.
Annual forecasts from 2026 to 2040, with phased uptake curves capturing launch, medium-term and long-term penetration dynamics.
Qualitative analysis in the accompanying executive deck covering disease background, epidemiology, the current treatment landscape, the evolving R&D pipeline, and the value case around healthcare costs potentially averted versus the current standard of care.
Intended audience:
The report is designed for business development and corporate strategy teams at ophthalmology-focused pharma companies; corporate development teams at the named pipeline companies; institutional investors with biotech ophthalmology positions; and payers modelling budget impact from 2028 onward for gene therapy in inherited retinal disease.
Next steps:
Sample slides, a detailed table of contents, and a complimentary 30-minute methodology walkthrough, available post-purchase, are available on request. Multi-seat licences and pre-publication pricing are available through 30 June 2026.
Contact: [email protected] | www.genescope-intelligence.com
Gene Scope Intelligence (www.genescope-intelligence.com) is a dedicated gene therapy market intelligence platform delivering in-depth commercial opportunity assessments, pipeline analyses and patient-based forecast models across key gene therapy indications in ophthalmology and beyond. Gene Scope Intelligence is a sister brand to VacZine Analytics, a strategic research publisher based in the United Kingdom since 2007, providing high-quality disease and commercial analysis to the pharmaceutical and biotech industries.
For more information, visit www.genescope-intelligence.com or contact [email protected] or [email protected].
Picture credit: Unsplash
VacZine Analytics® and Gene Scope Intelligence are trading divisions of Assay Advantage Ltd, UK Company No. 5807728.
Copyright 2026. All rights reserved.
